Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|March 27, 2026

The Workflow Guidance Gap Holding Back eClinical Ecosystems

In this video interview, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, examines why current eClinical technology too often prioritizes data flow over the day-to-day needs of users and what a truly guided workflow experience should look like for busy site teams.

Full interview summary

In a recent video interview with Applied Clinical Trials, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, discussed what defines an effective clinical trial tech stack in today's increasingly complex study environment and where the industry still has significant ground to cover. She opened by framing effective technology around two core principles: that tools must be purpose built for the specific tasks of clinical research, and that they must work together as an integrated ecosystem that simplifies execution rather than adding to the operational burden teams already carry.

Kole identified workflow guidance as the most underaddressed gap in current eClinical ecosystems, arguing that technology has become too focused on data flow and system architecture at the expense of the actual user experience. Sites running multiple concurrent trials need technology that actively guides them through each step of each study, reducing cognitive load and eliminating the workarounds and documentation gaps that emerge when systems are difficult to navigate.

She extended that thinking to the integration of digital and physical supply chains, making the case that the two must be treated as a single continuous system rather than separate operational domains. While digital supply chain tools have grown highly sophisticated, she emphasized that sponsors must honestly assess their in-house capabilities and lean on technology partners to configure, manage, and adapt those systems as real-world trial data replaces early enrollment assumptions.

Usability, Kole argued, is not a secondary concern but a direct driver of data quality and site performance. Systems that are intuitive and fast to navigate reduce errors, improve compliance, and keep busy site staff from deferring critical tasks. She closed by encouraging clinops leaders to think strategically about which innovations are likely to become standard and build those into their technology roadmaps accordingly, while managing truly one-off complexities through bespoke configuration rather than overloading their core platforms.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
© putilov_denis - © putilov_denis - stock.adobe.com
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.